📰 Upfront Payment News
Upfront Payment News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Upfront Payment. Real-time updates on events, politics, business and more.
May 3, 2024
Police are warning residents about potential door-to-door scams in Grand Rapids.
March 27, 2024
Setrusumab and Alvelestat Progress as Company Prepares for Transformative 2024
March 13, 2024
2023 revenue increased to a record $214.5 million2023 adjusted EBITDA increased to a record $72.9 millionSecured extension that will generate an estimated $1.3 billion in cash flow until 2053Announced...
February 20, 2024
Plans for a new laundromat on the Westside could be in trouble due to a $100,000 fee being charged by JEA.
February 1, 2024
Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV)Takeda Will Make...
January 31, 2024
Takeda and Protagonist Therapeutics, Inc. Enter into Worldwide License ...
January 22, 2024
In a recent development, the central government has introduced new revisions to the Mineral auction rules. These changes aim to ensure transparency and fair competition in the bidding process. According to the revised rules, the upfront payment for mineral auctions will now be capped at Rs 500 crore.
January 7, 2024
/PRNewswire/ -- Isomorphic Labs, a digital biology company with a mission to redefine drug discovery using the power of artificial intelligence, today...
December 26, 2023
DAEJEON, South Korea, December 26, 2023--LegoChem Biosciences Announces License Agreement for LCB84, a Trop2 directed ADC with Janssen Biotech, Inc., a Johnson & Johnson company.
December 20, 2023
Gilead Sciences, Inc. (Nasdaq: GILD) today announced an agreement with Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, headquartered in Holon, Israel, to exclusively license its potential first-in-class, pre-clinical antibody ...